Nateglinide is a medication that was first approved as a monotherapy for type 2 diabetes in 2001. It is currently approved for use alone or in combination with metformin, another leading oral anti-diabetic agent.
Brand name: Nateglinide is marketed as Starlix.
Drug class: Starlix belongs to a class of drugs called meglitinides. These drugs work to lower blood sugar levels by stimulating the pancreas to release more insulin. Effectiveness of meglitinides depends on how much glucose, or sugar, is present in the blood. Unlike a number of other diabetes treatments, Starlix causes the pancreas to release insulin only when glucose is present in the body, which can help patients avoid hypoglycemia.
Dosage: The recommended dose, when used alone or in combination with metformin, is 120 mg taken orally three times daily before meals.
Side effects: Possible common side effects of Starlix can include flu-like symptoms, upper respiratory infection, dizziness and joint pain.